摘要
目的探讨沙格列汀治疗新发2型糖尿病的临床疗效及安全性。方法在该院2012—2013年进行治疗的新发2型糖尿病患者中方便选取104例,根据治疗方法不同分为两组,每组52例,对照组52例患者应用二甲双胍治疗,观察组52例患者应用沙格列汀或加用二甲双胍治疗,比较两组治疗3个月血糖、体质量指数及糖化血红蛋白以及两组患者肝肾功能、胰岛素及胰岛素抵抗指数、不良反应情况。结果经过3个月的治疗,观察组FBG(7.3±1.3)mmol/L、PBG(10.4±2.2)mmol/L、Hb A1c(7.0±1.8)%、AST(37.1±2.66)U/L、HOMA-IR(5.1±0.5),对照组分别为(7.8±1.5)mmol/L、(10.7±2.8)mmol/L、(7.3±2.9)%、(37.7±2.4)U/L、(5.5±0.8),相比治疗前两组各指标明显降低,差异有统计学意义(t=3.986、5.624、4.012、6.254、5.043,P<0.05)。观察组不良反应发生率13.21%明显低于对照组,差异有统计学意义(χ~2=14.625,P<0.05)。结论沙格列汀对新发2型糖尿病患者有确切的疗效,能过有效降低患者血糖水平,同时改善胰岛素抵抗情况,不影响患者体重,且具有不良反应低的明显优势,具有较高的应用价值。
Objective This paper tries to investigate the clinical efficacy and safety of saxagliptin in the treatment of newly diagnosed type 2 diabetes. Methods 104 patients with newly diagnosed type 2 diabetes who were treated in the hospital from 2012 to 2013 were convenient selected and divided into two groups according to different treatment methods. 52 patients in each group.The control group was treated with metformin and the observation group adopted saxagliptin plus metformin treatment, and the blood glucose, body mass index and glycosylated hemoglobin in the two groups were compared for3 months, as well as liver and kidney function, insulin and insulin resistance index, and adverse reactions in both groups.Results After 3 months of treatment, observation group FBG（7.3±1.3） mmol/L, PBG（10.4±2.2） mmol/L, Hb A1 c（7.0±1.8）%,AST（37.1±2.66） U/L, HOMA-IR（5.1±0.5）. The control group was（7.8±1.5） mmol/L,（10.7±2.8） mmol/L,（7.3±2.9）%,（37.7± 2.4） U/L,（5.5 ± 0.8）, compared with the two indicators before treatment significantly reduced the difference was statistically significant（5.1±0.5）（t=3.986, 5.624, 4.012, 6.254, 5.043, P=0.05）. The incidence of adverse reactions in the observation group was significantly lower than the control group（13.21%）, and the difference was statistically significant（χ2=14.625, P〈0.05）. Conclusion Saxagliptin has a definite curative effect on newly diagnosed type 2 diabetic patients, which can effectively reduce blood glucose levels in patients, improve insulin resistance, does not affect patient weight, and has obvious advantages and low adverse reactions, and has high application value.
作者
卢健坤
温世宁
吴钧俊
LU Jian-kun;WEN Shi-ning;WU Jun-jun(Department of Endocrinology,Dongguan Dalang Hospital,Dongguan,Guangdong Province,523770 Chin)
出处
《中外医疗》
2018年第15期133-134,137,共3页
China & Foreign Medical Treatment
